<DOC>
	<DOCNO>NCT00002490</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell . It know whether receive either radiation therapy , chemotherapy , observation effective cancer bladder . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy , chemotherapy , observation follow tumor surgery treat patient bladder cancer .</brief_summary>
	<brief_title>Radiation Therapy , Chemotherapy , Observation Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy adjuvant radical radiotherapy v intravesical BCG mitomycin v observation alone endoscopic resection term progression rate survival patient stage I , grade 3 transitional cell carcinoma bladder . - Determine toxicity radical radiotherapy patient . - Determine incidence carcinoma situ elsewhere bladder correlation subsequent clinical outcome patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center , extent tumor ( single tumor without carcinoma situ ( CIS ) v multiple tumor CIS ) , WHO performance status . Patients single tumor CIS randomize arm I II . Patients multiple tumor CIS randomize arm II III . - Arm I : Patients undergo observation . - Arm II : Patients undergo radical radiotherapy 5 day week 6 week . Patients find node positive CT scan may undergo pelvic irradiation remain study . - Arm III : Patients receive intravesical BCG mitomycin ( discretion physician ) weekly 6-12 week . Patients arm I III follow 3 month randomization . All patient follow 6 , 9 , 12 month annually thereafter . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis transitional cell carcinoma bladder Stage T1 Nx M0 , grade 3 disease No muscle invasion base tumor Diagnosis stage make within past 6 month Earlier diagnosis tumor low stage grade allow No history high stage urothelial tumor Presence partial involvement bladder carcinoma situ ( CIS ) asymptomatic widespread CIS allow No widespread CIS cause severe symptom Prior complete transurethral resection tumor deep biopsy underlie bladder wall require Disease currently amenable adjuvant radiotherapy , follow cystoscopy biopsy PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior concurrent malignancy except nonmelanomatous skin cancer cervical intraepithelial neoplasia PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior adjuvant treatment intravesical BCG Chemotherapy : No 1 prior adjuvant treatment intravesical chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Diathermic removal associate small papillary growth allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>